By Roz Sweeney, Ph.D. Nerac Analyst, The recent Supreme Court decision on the Association for Molecular Pathology v. Myriad Genetics case was the culmination of much litigation on the validity of patent protection for the genomic sequences of BRCA1 and BRCA2. Myriad Genetics’ patents on these two genes gave it the exclusive right to offer genetic […]
By Donna Mitchell-Magaldi, Nerac Analyst,
The global medical device market was valued at $350 billion dollars in 2012 (Mddonline.com, 2012).
By Roz Sweeney, Ph.D. Nerac Analyst, Healthcare payers, both in the United States and Europe, have been striving to reduce costs in recent years, and this trend is expected to continue. To address this emphasis on cost-reduction, medical device companies are becoming increasingly interested in the market for technologies that reduce costs to the overall healthcare […]
By Roz Sweeney, Ph.D. Nerac Analyst,
Comprehensive evaluations of the clinical and technical literature serve a variety of purposes for medical device companies.